Skip to main content

Advertisement

SpringerLink
Log in

Pathologic Response to Preoperative Therapy: Does It Mean What We Think It Means?

  • EDUCATIONAL REVIEW– TRANSLATIONAL RESEARCH AND BIOMARKERS
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Tumors treated with preoperative chemotherapy or radiation often demonstrate evidence of response in the resection specimen. Pathologic response is often interpreted as a surrogate for recurrence or survival outcomes. With a valid surrogate for long-term outcomes, investigators can explore treatment strategies with immediate endpoints. The financial and time costs of trials measuring recurrence and survival may be lessened by using short-term pathologic outcomes as an endpoint. This review is intended to examine the current status of pathologic response as a surrogate for tumor behavior. We address questions regarding the definitions of pathologic response, as well as the current literature regarding the meaning of pathologic response for some common tumor types. We explore some of the potential confounding effects that may explain the frequent discordance between tumor response and patient outcomes. In addition, we address some alternative strategies to gauge the response of a tumor to preoperative therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Abratt RP, Brune D, Dimopoulos MA, Kliment J, Breza J, Selvaggi FP, et al. Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer. Ann Oncol. 2004;15:1613–21.

    Article  PubMed  CAS  Google Scholar 

  2. Blade J, Lopez-Guillermo A, Bosch F, Cervantes F, Reverter JC, Montserrat E, et al. Impact of response to treatment on survival in multiple myeloma: results in a series of 243 patients. Br J Haematol. 1994;88:117–21.

    Article  PubMed  CAS  Google Scholar 

  3. Horning SJ. Natural history of and therapy for the indolent non-Hodgkin’s lymphomas. Semin Oncol. 1993;20:75–88.

    PubMed  CAS  Google Scholar 

  4. Apple SK, Suthar F. How do we measure a residual tumor size in histopathology (the gold standard) after neoadjuvant chemotherapy? Breast. 2006;15:370–6.

    Article  PubMed  CAS  Google Scholar 

  5. Kuroi K, Toi M, Tsuda H, Kurosumi M, Akiyama F. Unargued issues on the pathological assessment of response in primary systemic therapy for breast cancer. Biomed Pharmacother. 2005;59:S387–92.

    Article  PubMed  Google Scholar 

  6. Kuroi K, Toi M, Tsuda H, Kurosumi M. Akiyama F. Issues in the assessment of the pathologic effect of primary systemic therapy for breast cancer. Breast Cancer. 2006;13:38–48.

    Article  PubMed  Google Scholar 

  7. Kurosumi M. Significance and problems in evaluations of pathological responses to neoadjuvant therapy for breast cancer. Breast Cancer. 2006;13:254–9.

    Article  PubMed  Google Scholar 

  8. Mansour JC, Tang L, Shah M, Bentrem D, Klimstra DS, Gonen M, et al. Does graded histologic response after neoadjuvant chemotherapy predict survival for completely resected gastric cancer? Ann Surg Oncol. 2007;14:3412–8.

    Article  PubMed  Google Scholar 

  9. Brenner B, Shah MA, Karpeh MS, Gonen M, Brennan MF, Coit DG, et al. A phase II trial of neoadjuvant cisplatin-fluorouracil followed by postoperative intraperitoneal floxuridine-leucovorin in patients with locally advanced gastric cancer. Ann Oncol. 2006;17:1404–11.

    Article  PubMed  CAS  Google Scholar 

  10. Imamura T, Iguchi H, Manabe T, Ohshio G, Yoshimura T, Wang ZH, et al. Quantitative analysis of collagen and collagen subtypes I, III, and V in human pancreatic cancer, tumor-associated chronic pancreatitis, and alcoholic chronic pancreatitis. Pancreas. 1995;11:357–64.

    Article  PubMed  CAS  Google Scholar 

  11. Aktepe F, Kapucuoglu N, Pak I. The effects of chemotherapy on breast cancer tissue in locally advanced breast cancer. Histopathology. 1996;29:63–7.

    Article  PubMed  CAS  Google Scholar 

  12. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005;23:3676–85.

    Article  PubMed  CAS  Google Scholar 

  13. Heys SD, Hutcheon AW, Sarkar TK, Ogston KN, Miller ID, Payne S, et al. Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast Cancer. 2002;3:S69–74.

    Article  PubMed  Google Scholar 

  14. Huober J, Krainick-Strobel U, Kurek R, Wallwiener D. Neoadjuvant endocrine therapy in primary breast cancer. Clin Breast Cancer. 2004;5:341–7.

    Article  PubMed  CAS  Google Scholar 

  15. Sataloff DM, Mason BA, Prestipino AJ, Seinige UL, Lieber CP, Baloch Z. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg. 1995;180:297–306.

    PubMed  CAS  Google Scholar 

  16. Hennessy BT, Gonzalez-Angulo AM, Hortobagyi GN, Cristofanilli M, Kau SW, Broglio K, et al. Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy. Cancer. 2006;106:1000–6.

    Article  PubMed  Google Scholar 

  17. Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997;15:2483–93.

    PubMed  CAS  Google Scholar 

  18. Hennessy BT, Hortobagyi GN, Rouzier R, Kuerer H, Sneige N, Buzdar AU, et al. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol. 2005;23:9304–11.

    Article  PubMed  Google Scholar 

  19. Kuerer HM, Newman LA, Buzdar AU, Hunt KK, Dhingra K, Buchholz TA, et al. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. Am J Surg. 1998;176:502–9.

    Article  PubMed  CAS  Google Scholar 

  20. Kuerer HM, Sahin AA, Hunt KK, Newman LA, Breslin TM, Ames FC, et al. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg. 1999;230:72–8.

    Article  PubMed  CAS  Google Scholar 

  21. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16:2672–85.

    PubMed  CAS  Google Scholar 

  22. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999;17:460–9.

    PubMed  CAS  Google Scholar 

  23. Bertheau P, Lerebours F, Mounier N, de Roquancourt A, Espié M, et al. Prognostic significance of a combined clinicopathologic score for response to primary systemic therapy in locally advanced breast cancer. Oncol Rep. 2005;14:513–20.

    PubMed  Google Scholar 

  24. Huang EH, Tucker SL, Strom EA, McNeese MD, Kuerer HM, Hortobagyi GN, et al. Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys. 2005;62:351–7.

    PubMed  Google Scholar 

  25. Ellis P, Smith I, Ashley S, Walsh G, Ebbs S, Baum M, et al. Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer. J Clin Oncol. 1998;16:107–14.

    PubMed  CAS  Google Scholar 

  26. Buchholz TA, Tucker SL, Masullo L, Kuerer HM, Erwin J, Salas J, et al. Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation. J Clin Oncol. 2002;20:17–23.

    Article  PubMed  CAS  Google Scholar 

  27. Pierga JY, Mouret E, Dieras V, Laurence V, Beuzeboc P, Dorval T, et al. Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer. Br J Cancer. 2000;83:1480–7.

    Article  PubMed  CAS  Google Scholar 

  28. Neville AM, Bettelheim R, Gelber RD, Säve-Söderbergh J, Davis BW, Reed R, et al. Factors predicting treatment responsiveness and prognosis in node-negative breast cancer. The International (Ludwig) Breast Cancer Study Group. J Clin Oncol. 1992;10:696–705.

    PubMed  CAS  Google Scholar 

  29. Castiglione-Gertsch M, Johnsen C, Goldhirsch A, Gelber RD, Rudenstam CM, Collins J, et al. The International (Ludwig) Breast Cancer Study Group Trials I–IV: 15 years follow-up. Ann Oncol. 1994;5:717–24.

    PubMed  CAS  Google Scholar 

  30. Barista I, Baltali E, Güllü IH, Güler N, Celik I, Saraçbaşi O, et al. Factors influencing the distribution of metastases and survival in metastatic breast carcinoma. Am J Clin Oncol. 1996;19:569–73.

    Article  PubMed  CAS  Google Scholar 

  31. Mazouni C, Kau SW, Frye D, Andre F, Kuerer HM, Buchholz TA, et al. Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers. Ann Oncol. 2007;18:874–80.

    Article  PubMed  CAS  Google Scholar 

  32. Fisher ER, Wang J, Bryant J, Fisher B, Mamounas E, Wolmark N. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer. 2002;95:681–95.

    Article  PubMed  Google Scholar 

  33. Cocquyt VF, Blondeel PN, Depypere HT, Praet MM, Schelfhout VR, Silva OE, et al. Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma. Eur J Surg Oncol. 2003;29:361–7.

    Article  PubMed  CAS  Google Scholar 

  34. Tubiana-Hulin M, Stevens D, Lasry S, Guinebretière JM, Bouita L, Cohen-Solal C, et al. Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution. Ann Oncol. 2006;17:1228–33.

    Article  PubMed  CAS  Google Scholar 

  35. Akazawa K, Tamaki Y, Taguchi T, Tanji Y, Miyoshi Y, Kim SJ, et al. Preoperative evaluation of residual tumor extent by three-dimensional magnetic resonance imaging in breast cancer patients treated with neoadjuvant chemotherapy. Breast J. 2006;12:130–7.

    Article  PubMed  Google Scholar 

  36. Bottini A, Berruti A, Tampellini M, Morrica B, Brunelli A, Gnocchi E, et al. Influence of neoadjuvant chemotherapy on serum tumor markers CA 15-3, MCA, CEA, TPS and TPA in breast cancer patients with operable disease. Tumour Biol. 1997;18:301–10.

    Article  PubMed  CAS  Google Scholar 

  37. Kanazawa T, Akashi-Tanaka S, Iwamoto E, Takasugi M, Shien T, Kinoshita T, et al. Diagnosis of complete response to neoadjuvant chemotherapy using diagnostic imaging in primary breast cancer patients. Breast J. 2005;11:311–6.

    Article  PubMed  Google Scholar 

  38. Kwong MS, Chung GG, Horvath LJ, Ward BA, Hsu AD, Carter D, et al. Postchemotherapy MRI overestimates residual disease compared with histopathology in responders to neoadjuvant therapy for locally advanced breast cancer. Cancer J. 2006;12:212–21.

    Article  PubMed  Google Scholar 

  39. Segara D, Krop IE, Garber JE, Winer E, Harris L, Bellon JR, et al. Does MRI predict pathologic tumor response in women with breast cancer undergoing preoperative chemotherapy? J Surg Oncol. 2007;96:474–80.

    Article  PubMed  Google Scholar 

  40. Tozaki M, Uno S, Kobayashi T, Aiba K, Yoshida K, Takeyama H, et al. Histologic breast cancer extent after neoadjuvant chemotherapy: comparison with multidetector-row CT and dynamic MRI. Radiat Med. 2004;22:246–53.

    PubMed  Google Scholar 

  41. Vinnicombe SJ, MacVicar AD, Guy RL, Sloane JP, Powles TJ, Knee G, et al. Primary breast cancer: mammographic changes after neoadjuvant chemotherapy, with pathologic correlation. Radiology. 1996;198:333–40.

    PubMed  CAS  Google Scholar 

  42. Abraham DC, Jones RC, Jones SE, Cheek JH, Peters GN, Knox SM, et al. Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging. Cancer. 1996;78:91–100.

    Article  PubMed  CAS  Google Scholar 

  43. Rousseau C, Devillers A, Sagan C, Ferrer L, Bridji B, Campion L, et al. Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography. J Clin Oncol. 2006;24:5366–72.

    Article  PubMed  Google Scholar 

  44. Ajani JA, Komaki R, Putnam JB, Walsh G, Nesbitt J, Pisters PW, et al. A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. Cancer. 2001;92:279–86.

    Article  PubMed  CAS  Google Scholar 

  45. Ajani JA, Walsh G, Komaki R, Morris J, Swisher SG, Putnam JB Jr, et al. Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction. Cancer. 2004;100:2347–54.

    Article  PubMed  CAS  Google Scholar 

  46. Ancona E, Ruol A, Santi S, Merigliano S, Sileni VC, Koussis H, et al. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer. 2001;91:2165–74.

    Article  PubMed  CAS  Google Scholar 

  47. Chirieac LR, Swisher SG, Ajani JA, Komaki RR, Correa AM, Morris JS, et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer. 2005;103:1347–55.

    Article  PubMed  Google Scholar 

  48. Donington JS, Miller DL, Allen MS, Deschamps C, Nichols FC 3rd, Pairolero PC. Tumor response to induction chemoradiation: influence on survival after esophagectomy. Eur J Cardiothorac Surg. 2003;24:631–6;discussion 636–7.

    Article  PubMed  Google Scholar 

  49. Gu Y, Swisher SG, Ajani JA, Correa AM, Hofstetter WL, Liao Z, et al. The number of lymph nodes with metastasis predicts survival in patients with esophageal or esophagogastric junction adenocarcinoma who receive preoperative chemoradiation. Cancer. 2006;106:1017–25.

    Article  PubMed  Google Scholar 

  50. Rohatgi PR, Swisher SG, Correa AM, Wu TT, Liao Z, Komaki R, et al. Failure patterns correlate with the proportion of residual carcinoma after preoperative chemoradiotherapy for carcinoma of the esophagus. Cancer. 2005;104:1349–55.

    Article  PubMed  Google Scholar 

  51. Wang KL, Yang Q, Cleary KR, Swisher SG, Correa AM, Komaki R, et al. The significance of neuroendocrine differentiation in adenocarcinoma of the esophagus and esophagogastric junction after preoperative chemoradiation. Cancer. 2006;107:1467–74.

    Article  PubMed  Google Scholar 

  52. Geh JI, Bond SJ, Bentzen SM, Glynne-Jones R. Systematic overview of preoperative (neoadjuvant) chemoradiotherapy trials in oesophageal cancer: evidence of a radiation and chemotherapy dose response. Radiother Oncol. 2006;78:236–44.

    Article  PubMed  CAS  Google Scholar 

  53. Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994;73:2680–6.

    Article  PubMed  CAS  Google Scholar 

  54. Posner MC, Gooding WE, Landreneau RJ, Rosenstein MM, Clarke MR, Peterson MS, et al. Preoperative chemoradiotherapy for carcinoma of the esophagus and gastroesophageal junction. Cancer J Sci Am. 1998;4:237–46.

    PubMed  CAS  Google Scholar 

  55. Schneider PM, Baldus SE, Metzger R, Kocher M, Bongartz R, Bollschweiler E, et al. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification. Ann Surg. 2005;242:684–92.

    Article  PubMed  Google Scholar 

  56. Swisher SG, Hofstetter W, Wu TT, Correa AM, Ajani JA, Komaki RR, et al. Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT). Ann Surg. 2005;241:810–7;discussion 817–20.

    Article  PubMed  Google Scholar 

  57. Berger AC, Farma J, Scott WJ, Freedman G, Weiner L, Cheng JD, et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol. 2005;23:4330–7.

    Article  PubMed  Google Scholar 

  58. Korst RJ, Kansler AL, Port JL, Lee PC, Kerem Y, Altorki NK. Downstaging of T or N predicts long-term survival after preoperative chemotherapy and radical resection for esophageal carcinoma. Ann Thorac Surg. 2006;82:480–4; discussion 484–5.

    Article  PubMed  Google Scholar 

  59. Rizk NP, Venkatraman E, Bains MS, Park B, Flores R, Tang L, et al. American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma. J Clin Oncol. 2007;25:507–12.

    Article  PubMed  Google Scholar 

  60. Duong C, Greenawalt DM, Kowalczyk A, Ciavarella ML, Raskutti G, Murray WK, et al. Pretreatment gene expression profiles can be used to predict response to neoadjuvant chemoradiotherapy in esophageal cancer. Ann Surg Oncol. 2007;14:3602–9.

    Article  PubMed  Google Scholar 

  61. Kato H, Fukuchi M, Miyazaki T, Nakajima M, Tanaka N, Inose T, et al. Prediction of response to definitive chemoradiotherapy in esophageal cancer using positron emission tomography. Anticancer Res. 2007;27:2627–33.

    PubMed  Google Scholar 

  62. Yang Q, Cleary KR, Yao JC, Swisher SG, Roth JA, Lynch PM, et al. Significance of post-chemoradiation biopsy in predicting residual esophageal carcinoma in the surgical specimen. Dis Esophagus. 2004;17:38–43.

    Article  PubMed  CAS  Google Scholar 

  63. Swisher SG, Erasmus J, Maish M, Correa AM, Macapinlac H, Ajani JA, et al. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer. 2004;101:1776–85.

    Article  PubMed  Google Scholar 

  64. Ott K, Weber WA, Lordick F, Becker K, Busch R, Herrmann K, et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol. 2006;24:4692–8.

    Article  PubMed  Google Scholar 

  65. Lavin PT, Bruckner HW, Plaxe SC. Studies in prognostic factors relating to chemotherapy for advanced gastric cancer. Cancer. 1982;50:2016–23.

    Article  PubMed  CAS  Google Scholar 

  66. Lowy AM, Mansfield PF, Leach SD, Pazdur R, Dumas P, Ajani JA. Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg. 1999;229:303–8.

    Article  PubMed  CAS  Google Scholar 

  67. Ajani JA, Mansfield PF, Janjan N, Morris J, Pisters PW, Lynch PM, et al. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol. 2004;22:2774–80.

    Article  PubMed  CAS  Google Scholar 

  68. Ajani JA, Mansfield PF, Crane CH, Wu TT, Lunagomez S, Lynch PM, et al. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol. 2005;23:1237–44.

    Article  PubMed  CAS  Google Scholar 

  69. Ajani JA, Winter K, Okawara GS, Donohue JH, Pisters PW, Crane CH, et al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol. 2006;24:3953–8.

    Article  PubMed  CAS  Google Scholar 

  70. Dehdashti F, Siegel BA. Neoplasms of the esophagus and stomach. Semin Nucl Med. 2004;34:198–208.

    Article  PubMed  Google Scholar 

  71. Herrmann K, Ott K, Buck AK, Lordick F, Wilhelm D, Souvatzoglou M, et al. Imaging gastric cancer with PET and the radiotracers 18F-FLT and 18F-FDG: A comparative analysis. J Nucl Med. 2007;48:1945–50.

    Article  PubMed  CAS  Google Scholar 

  72. Mukai K, Ishida Y, Okajima K, Isozaki H, Morimoto T, Nishiyama S. Usefulness of preoperative FDG-PET for detection of gastric cancer. Gastric Cancer. 2006;9:192–6.

    Article  PubMed  Google Scholar 

  73. Ott K, Fink U, Becker K, Stahl A, Dittler HJ, Busch R, et al. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol. 2003;21:4604–10.

    Article  PubMed  CAS  Google Scholar 

  74. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43–66.

    Article  PubMed  Google Scholar 

  75. Rubbia-Brandt L, Giostra E, Brezault C, Roth AD, Andres A, Audard V, et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol. 2007;18:299–304.

    Article  PubMed  CAS  Google Scholar 

  76. Allen PJ, Kemeny N, Jarnagin W, DeMatteo R, Blumgart L, Fong Y. Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. J Gastrointest Surg. 2003;7:109–15; discussion 116–7.

    Article  PubMed  Google Scholar 

  77. Grothey A, Hedrick EE, Mass RD, Sarkar S, Suzuki S, Ramanathan RK, et al. Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. J Clin Oncol. 2008;26:183–9.

    Article  PubMed  CAS  Google Scholar 

  78. Engstrom PF. NCCN clinical practice guidelines in oncology-rectal cancer. NCCN clinical practice guidelines in oncology, National Comprehensive Cancer Network, 2007.

  79. Kuo LJ, Liu MC, Jian JJ, Horng CF, Cheng TI, Chen CM, et al. Is final TNM staging a predictor for survival in locally advanced rectal cancer after preoperative chemoradiation therapy? Ann Surg Oncol. 2007;14:2766–72.

    Article  PubMed  Google Scholar 

  80. Pucciarelli S, Capirci C, Emanuele U, Toppan P, Friso ML, Pennelli GM, et al. Relationship between pathologic T-stage and nodal metastasis after preoperative chemoradiotherapy for locally advanced rectal cancer. Ann Surg Oncol. 2005;12:111–6.

    Article  PubMed  Google Scholar 

  81. Read TE, McNevin MS, Gross EK, Whiteford HM, Lewis JL, Ratkin G, et al. Neoadjuvant therapy for adenocarcinoma of the rectum: tumor response and acute toxicity. Dis Colon Rectum. 2001;44:513–22.

    Article  PubMed  CAS  Google Scholar 

  82. Read TE, Andujar JE, Caushaj PF, Johnston DR, Dietz DW, Myerson RJ, et al. Neoadjuvant therapy for rectal cancer: histologic response of the primary tumor predicts nodal status. Dis Colon Rectum. 2004;47:825–31.

    Article  PubMed  Google Scholar 

  83. Rengan R, Paty PB, Wong WD, Guillem JG, Weiser M, Temple L, et al. Ten-year results of preoperative radiation followed by sphincter preservation for rectal cancer: increased local failure rate in nonresponders. Clin Colorectal Cancer. 2006;5:413–21.

    Article  PubMed  Google Scholar 

  84. Stipa F, Chessin DB, Shia J, Paty PB, Weiser M, Temple LK, et al. A pathologic complete response of rectal cancer to preoperative combined-modality therapy results in improved oncological outcome compared with those who achieve no downstaging on the basis of preoperative endorectal ultrasonography. Ann Surg Oncol. 2006;13:1047–53.

    Article  PubMed  Google Scholar 

  85. Berger C, de Muret A, Garaud P, Chapet S, Bourlier P, Reynaud-Bougnoux A, et al. Preoperative radiotherapy (RT) for rectal cancer: predictive factors of tumor downstaging and residual tumor cell density (RTCD): prognostic implications. Int J Radiat Oncol Biol Phys. 1997;37:619–27.

    PubMed  CAS  Google Scholar 

  86. Das P, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Wolff RA, et al. Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer. Cancer. 2007;109:1750–5.

    Article  PubMed  CAS  Google Scholar 

  87. Park YA, Sohn SK, Seong J, Baik SH, Lee KY, Kim NK, et al. Serum CEA as a predictor for the response to preoperative chemoradiation in rectal cancer. J Surg Oncol. 2006;93:145–50.

    Article  PubMed  Google Scholar 

  88. Bozzetti F, Andreola S, Baratti D, Mariani L, Stani SC, Valvo F, et al. Preoperative chemoradiation in patients with resectable rectal cancer: results on tumor response. Ann Surg Oncol. 2002;9:444–9.

    Article  PubMed  Google Scholar 

  89. Vanagunas A, Lin DE, Stryker SJ. Accuracy of endoscopic ultrasound for restaging rectal cancer following neoadjuvant chemoradiation therapy. Am J Gastroenterol. 2004;99:109–12.

    Article  PubMed  Google Scholar 

  90. Habr-Gama A, Perez RO, Nadalin W, Nahas SC, Ribeiro U Jr, Silva E Sousa AH Jr, et al. Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival. J Gastrointest Surg. 2005;9:90–9; discussion 99–101.

    Article  PubMed  Google Scholar 

  91. Hiotis SP, Weber SM, Cohen AM, Minsky BD, Paty PB, Guillem JG, et al. Assessing the predictive value of clinical complete response to neoadjuvant therapy for rectal cancer: an analysis of 488 patients. J Am Coll Surg. 2002;194:131–5; discussion 135–6.

    Article  PubMed  Google Scholar 

  92. Moore HG, Gittleman AE, Minsky BD, Wong D, Paty PB, Weiser M, et al. Rate of pathologic complete response with increased interval between preoperative combined modality therapy and rectal cancer resection. Dis Colon Rectum. 2004;47–86.

  93. Pucciarelli S, Toppan P, Friso ML, Russo V, Pasetto L, Urso E, et al. Complete pathologic response following preoperative chemoradiation therapy for middle to lower rectal cancer is not a prognostic factor for a better outcome. Dis Colon Rectum. 2004;47:1798–807.

    Article  PubMed  Google Scholar 

  94. Compton CC, Fielding LP, Burgart LJ, Conley B, Cooper HS, Hamilton SR, et al. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000;124:979–94.

    PubMed  CAS  Google Scholar 

  95. Onaitis MW, Noone RB, Fields R, Hurwitz H, Morse M, Jowell P, et al. Complete response to neoadjuvant chemoradiation for rectal cancer does not influence survival. Ann Surg Oncol. 2001;8:801–6.

    Article  PubMed  CAS  Google Scholar 

  96. Wiig JN, Larsen SG, Dueland S, Giercksky KE. Clinical outcome in patients with complete pathologic response (pT0) to preoperative irradiation/chemo-irradiation operated for locally advanced or locally recurrent rectal cancer. J Surg Oncol. 2005;92:70–5.

    Article  PubMed  Google Scholar 

  97. Rodel C, Martus P, Papadoupolos T, Füzesi L, Klimpfinger M, Fietkau R, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol. 2005;23:8688–96.

    Article  PubMed  Google Scholar 

  98. Breslin TM, Hess KR, Harbison DB, Jean ME, Cleary KR, Dackiew AP, et al. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol. 2001;8:123–32.

    Article  PubMed  CAS  Google Scholar 

  99. White RR, Xie HB, Gottfried MR, Czito BG, Hurwitz HI, Morse MA, et al. Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer. Ann Surg Oncol. 2005;12:214–21.

    Article  PubMed  Google Scholar 

  100. Antonescu CR, Besmer P, Guo T, Arkun K, Hom G, Koryotowski B, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res. 2005;11:4182–90.

    Article  PubMed  CAS  Google Scholar 

  101. Blagosklonny MV. Why therapeutic response may not prolong the life of a cancer patient: selection for oncogenic resistance. Cell Cycle. 2005;4:1693–8.

    PubMed  CAS  Google Scholar 

  102. Blagosklonny MV. Antiangiogenic therapy and tumor progression. Cancer Cell. 2004;5:13–7.

    Article  PubMed  CAS  Google Scholar 

  103. Bedi A, Zehnbauer BA, Collector MI, Barber JP, Zicha MS, Sharkis SJ, et al. BCR-ABL gene rearrangement and expression of primitive hematopoietic progenitors in chronic myeloid leukemia. Blood. 1993;81:2898–902.

    PubMed  CAS  Google Scholar 

  104. Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J, Tanhehco Y, et al. Characterization of clonogenic multiple myeloma cells. Blood. 2004;103:2332–6.

    Article  PubMed  CAS  Google Scholar 

  105. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003;100:3983–8.

    Article  PubMed  CAS  Google Scholar 

  106. Hemmati HD, Nakano I, Lazareff JA, Masterman-Smith M, Geschwind DH, Bronner-Fraser M, et al. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci USA. 2003;100:15178–83.

    Article  PubMed  CAS  Google Scholar 

  107. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003;63:5821–8.

    PubMed  CAS  Google Scholar 

  108. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, et al. Identification of pancreatic cancer stem cells. Cancer Res. 2007;67:1030–7.

    Article  PubMed  CAS  Google Scholar 

  109. Avital I, Moreira AL, Klimstra DS, Leversha M, Papdopoulos EB, Brennan M, et al. Donor-derived human bone marrow cells contribute to solid organ cancers developing after bone marrow transplantation. Stem Cells. 2007;25:2903–9.

    Article  PubMed  Google Scholar 

  110. Erasmus JJ, Munden RF, Truong MT, Ho JJ, Hofstetter WL, Macapinlac HA, et al. Preoperative chemo-radiation-induced ulceration in patients with esophageal cancer: a confounding factor in tumor response assessment in integrated computed tomographic-positron emission tomographic imaging. J Thorac Oncol. 2006;1:478–86.

    Article  PubMed  Google Scholar 

  111. Tan MC, Linehan DC, Hawkins WG, Siegel BA, Strasberg SM. Chemotherapy-induced normalization of FDG uptake by colorectal liver metastases does not usually indicate complete pathologic response. J Gastrointest Surg. 2007;11:1112–9.

    Article  PubMed  Google Scholar 

  112. Kang CM, Kim JY, Choi GH, Kim KS, Choi JS, Lee WJ, et al. The use of adjusted preoperative CA 19–9 to predict the recurrence of resectable pancreatic cancer. J Surg Res. 2007;140:31–5.

    Article  PubMed  CAS  Google Scholar 

  113. Borowitz M, Westra W, Cooley LD, et al. Pathology and laboratory medicine. In: Abeloff MD, editor. Clinical oncology. Philadelphia: Elsevier; 2004.

    Google Scholar 

  114. Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: a decade of discovery—what we have learned and where we are going. J Urol. 1999;162:293–306.

    Article  PubMed  CAS  Google Scholar 

  115. Goral V, Yesilbagdan H, Kaplan A, Sit D. Evaluation of CA 72-4 as a new tumor marker in patients with gastric cancer. Hepatogastroenterology. 2007;54:1272–5.

    PubMed  CAS  Google Scholar 

  116. Li N, Zhang J, Liang Y, Shao J, Peng F, Sun M, et al. A controversial tumor marker: is SM22 a proper biomarker for gastric cancer cells? J Proteome Res. 2007;6:3304–12.

    Article  PubMed  CAS  Google Scholar 

  117. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006;24:5313–27.

    Article  PubMed  CAS  Google Scholar 

  118. Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland EK, Tempero MA. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer. 2005;93:195–9.

    Article  PubMed  CAS  Google Scholar 

  119. Micke O, Bruns F, Kurowski R, Horst E, deVries AF, Hausler JW, et al. Predictive value of carbohydrate antigen 19-9 in pancreatic cancer treated with radiochemotherapy. Int J Radiat Oncol Biol Phys. 2003;57:90–7.

    PubMed  CAS  Google Scholar 

  120. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230:309–18; discussion 318–21.

    Article  PubMed  CAS  Google Scholar 

  121. Lowy AM, Feig BW, Janjan N, Rich TA, Pisters PW, Ajani JA, et al. A pilot study of preoperative chemoradiotherapy for resectable gastric cancer. Ann Surg Oncol. 2001;8:519–24.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgment

This project was supported in part by the NIH UL1 RR024982 grant.

Author information

Authors and Affiliations

  1. Division of Surgical Oncology, Harold C. Simmons Cancer Center, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA

    John C. Mansour MD & Roderich E. Schwarz MD, PhD

Authors
  1. John C. Mansour MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roderich E. Schwarz MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John C. Mansour MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mansour, J.C., Schwarz, R.E. Pathologic Response to Preoperative Therapy: Does It Mean What We Think It Means?. Ann Surg Oncol 16, 1465–1479 (2009). https://doi.org/10.1245/s10434-009-0374-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-009-0374-z

Keywords

Search

Navigation